181 related articles for article (PubMed ID: 23276803)
1. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; Soriano V
AIDS; 2013 Apr; 27(7):1129-34. PubMed ID: 23276803
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
4. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
5. Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
Sanmartin R; de Felipe E; Tor J; Sanvicens A; Barluenga E; Martinez E; Muga R; Jou A; Ojanguren I; López JJ; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1235-43. PubMed ID: 22443303
[TBL] [Abstract][Full Text] [Related]
6. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
[TBL] [Abstract][Full Text] [Related]
7. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
Connoy A; Turner J; Núñez M
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
[TBL] [Abstract][Full Text] [Related]
8. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
[TBL] [Abstract][Full Text] [Related]
9. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
Fernández-Montero JV; Vispo E; Barreiro P; Sierra-Enguita R; de Mendoza C; Labarga P; Soriano V
Clin Infect Dis; 2014 Jun; 58(11):1549-53. PubMed ID: 24633686
[TBL] [Abstract][Full Text] [Related]
11. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
[TBL] [Abstract][Full Text] [Related]
12. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
[TBL] [Abstract][Full Text] [Related]
13. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome.
Castellares C; Barreiro P; Martín-Carbonero L; Labarga P; Vispo ME; Casado R; Galindo L; García-Gascó P; García-Samaniego J; Soriano V
J Viral Hepat; 2008 Mar; 15(3):165-72. PubMed ID: 18233989
[TBL] [Abstract][Full Text] [Related]
14. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
15. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy.
Cartón JA; Collazos J; de la Fuente B; Asensi V
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):215-22. PubMed ID: 22734850
[TBL] [Abstract][Full Text] [Related]
16. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
[TBL] [Abstract][Full Text] [Related]
17. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D; Planas R; Muga R; Ballesteros AL; Santos J; Tor J; Sirera G; Guardiola H; Salas A; Cabré E; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Tural C
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1293-7. PubMed ID: 15650421
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.
Schiavini M; Angeli E; Mainini A; Zerbi P; Duca PG; Gubertini G; Vago L; Fociani P; Giorgi R; Cargnel A
HIV Med; 2006 Jul; 7(5):331-7. PubMed ID: 16945079
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
